Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Velimir A. Luketic, Juan F. Gallegos‐Orozco et al.|Gastroenterology|2016Cited by 1k
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary CholangitisChristophe Corpechot, Raoul Poupon, Olivier Chazouillères et al.|New England Journal of Medicine|2018Cited by 605
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stefan Zeuzem, Peter Buggisch et al.|New England Journal of Medicine|2017Cited by 565
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver DiseaseHuapeng Lin, Hye Won Lee, Terry Cheuk‐Fung Yip et al.|JAMA|2024Cited by 200
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis deltaDominique Roulot, Sophie Hillaire, Ségolène Brichler et al.|Journal of Hepatology|2020Cited by 151